CENTRALPHL Central Pharmaceuticals Limited
Pharmaceuticals & Chemicals
Tk 8.6 as of 2026-11-12 14:07:07
Rank 346 of all scored
Data completeness 70%
Data completeness 70%
Override: Avoid. Last year was a net loss.
Score breakdown
Consistency 32
Profitability 0
Solvency 91
Valuation 32
Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method
Why this score
Strengths
- Consistency EPS grew in 3 of 4 years
- Solvency Low debt: debt/equity 0.33x (below 0.5)
- Valuation Trades near book value (P/NAV 1.28x)
Concerns
- Consistency Net loss in 5 of the last 5 years
- Consistency Dividend paid in only 0 of 5 years
- Profitability Average ROE only -5.91% (below 10%: capital not working hard)
- Profitability Last year was a net LOSS of Tk 2.2 cr
- Valuation No P/E: the company is loss-making
Risk flags
- Category Z (poor/defaulting: gambling favourite, avoid for long-term)
- Small cap (< Tk 200 cr): most exposed to manipulation and volatility
- Thin trading (last day ~Tk 0.16 cr)
- Low sponsor/director holding (7.67%): weak commitment
- Retail holds 85.17%: retail takes the damage if it goes wrong
Valuation
P/E
P/E audited
P/E current
P/B
NAV per share
EPS (last audited year)
Graham fair value
Margin of safety
52-week range
21.1% above the low, 31.2% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.
Quality and growth
ROE
ROE avg
ROE min
Profit CAGR
Profit YoY
Net profit
EPS up
Loss years (last ~5)
Dividends and safety
Div years
Dividend yield
Payout
Cash div
D/E
Loans/MCap
Size, liquidity and ownership
MCap
Free float
Daily turnover
Sponsor %
Inst. %
Public %
Foreign %
Shareholding
- Sponsor/director 7.7%
- Institution 7.2%
- Public 85.2%
Audited history
| Year | EPS (Tk) | NAV/share | Net profit (cr) | Cash div % | Bonus % |
|---|---|---|---|---|---|
| 2021 | -0.07 | 6.53 | -1 | — | — |
| 2022 | -0.57 | 5.96 | -7 | — | — |
| 2023 | -0.37 | 5.59 | -4 | — | — |
| 2024 | -0.35 | 7.06 | -4 | — | — |
| 2025 | -0.18 | 6.87 | -2 | — | — |
Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.
Shariah screen (partial)
Business screen and the debt ratio (loans / market cap 26.1%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.
Educational, not investment advice. Verify on DSE and StockNow before making any decision.